Explore

FDA Approves Tukysa Regimen for First-Line Maintenance Treatment of HER2-Positive Metastatic Breast Cancer

FDA Approves Tukysa Regimen for First-Line Maintenance Treatment of HER2-Positive Metastatic Breast Cancer

The FDA has approved Tukysa (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. This approval expands the use of Tukysa to the frontline setting, offering a new chemotherapy-free maintenance treatment option. The decision is based on findings from the HER2CLIMB-05 trial, a randomized phase 3 study, which demonstrated a significant improvement in progression-free survival. Patients receiving the Tukysa regimen experienced a median progression-free survival of 24.9 months compared to 16.3 months with placebo, trastuzumab, and pertuzumab, representing an 8.6-month difference. This marks a shift in the treatment landscape for HER2-positive metastatic breast cancer, moving the oral therapy into an earlier treatment window.

Fred Hutch Researchers Identify Key Driver in Aggressive Prostate Cancer, Suggesting New Treatment Avenues

Fred Hutch Researchers Identify Key Driver in Aggressive Prostate Cancer, Suggesting New Treatment Avenues

Researchers at Fred Hutch Cancer Center have identified a key driver in aggressive prostate cancer, publishing their findings in the journal Nature. The study, led by first author Yeon Soo Kim, PhD, a postdoctoral researcher in Dr. Hsieh’s lab, reveals that a single transfer RNA (tRNA) can control the identity of prostate cancer cells. Prostate cancer often becomes aggressive and resistant to standard therapies when it shifts from an androgen receptor-dependent state to an androgen receptor-independent state. The research found that a specific tRNA, tRNA 1 Arg(UCU), is abundant in androgen receptor-dependent cells but diminishes in treatment-resistant tumors. Crucially, experiments showed that reintroducing this specific tRNA to treatment-resistant tumors could revert them to a state sensitive to androgen receptor-targeting therapies. This discovery suggests a novel mechanism by which prostate cancer cells change their identity and develop drug resistance, offering a potential new pathway for therapeutic i...

Lila Bio Appoints Kimberly Ma as Chief Development Officer to Advance AI-Driven Radiopharmaceuticals

Lila Bio Appoints Kimberly Ma as Chief Development Officer to Advance AI-Driven Radiopharmaceuticals

Lila Bio Appoints Kimberly Ma as Chief Development Officer to Advance AI-Driven Radiopharmaceuticals

Pfizer's Tukysa Regimen Receives FDA Approval for Earlier Breast Cancer Treatment

Pfizer's Tukysa Regimen Receives FDA Approval for Earlier Breast Cancer Treatment

Pfizer's Tukysa Regimen Receives FDA Approval for Earlier Breast Cancer Treatment

CURE Magazine Explores the True Meaning and Misconceptions of 'Five-Year Survival' in Cancer Treatment

CURE Magazine Explores the True Meaning and Misconceptions of 'Five-Year Survival' in Cancer Treatment

CURE magazine has published an article titled 'What Five Years Really Means,' delving into the common term 'five-year survival' in cancer treatment and clarifying its implications. The author, a colorectal cancer survivor, reflects on reaching her own five-year milestone and the varying emotional responses to such anniversaries. The article explains that 'five-year survival' is a benchmark used by doctors and researchers to compare cases and is not synonymous with a 'five-year cure.' It highlights that this statistic refers to the percentage of people in studies who were alive five years after diagnosis, not a prediction of individual lifespan. The piece also notes that the significance of the five-year mark can vary depending on the type of cancer, with some cancers having critical periods earlier or later than five years. Experts quoted, including epidemiologist Phyllis Wingo, PhD, and Dr. Alan Venook, emphasize that while it's an important landmark, it doesn't mean a patient will only live five years or...

Med Center Health Becomes First in Region to Offer New Prostate Cancer Treatment

Med Center Health Becomes First in Region to Offer New Prostate Cancer Treatment

Med Center Health in Bowling Green, Kentucky, has become the first healthcare provider in the region to offer a new prostate cancer treatment. This development means that patients seeking this advanced treatment no longer need to travel outside the local area, as care is now available within Bowling Green. The introduction of this treatment has already led to patients transferring their care to Med Center Health to access the new local option. The specific details of the treatment, such as its name or methodology, were not provided in the summary, but its availability marks a significant advancement in local cancer care.

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

UCLA Researcher Dr. Dennis Slamon Awarded 2026 Albany Prize for Cancer Therapy Discoveries

UCLA Researcher Dr. Dennis Slamon Awarded 2026 Albany Prize for Cancer Therapy Discoveries

Dr. Dennis Slamon, a distinguished oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been honored with the 2026 Albany Prize. He shares this prestigious award with Dr. Tony Hunter of the Salk Institute for Biological Studies. The prize recognizes their groundbreaking discoveries in cancer biology, which have significantly advanced the understanding of cancer's molecular mechanisms and led to life-saving treatments. Dr. Slamon is particularly recognized for his research that identified HER2-positive (HER2+) breast cancer and subsequently led to the development of Herceptin, the first targeted treatment for this aggressive form of breast cancer. His work also contributed to the development of CDK4/6 inhibitors for hormone receptor-positive breast cancer.

Patricia's Battle with Small Cell Lung Cancer Highlights Promise of T-Cell Engager Clinical Trial at Roswell Park

Patricia's Battle with Small Cell Lung Cancer Highlights Promise of T-Cell Engager Clinical Trial at Roswell Park

Patricia, a patient at Roswell Park Comprehensive Cancer Center, is experiencing an exceptional response to a Phase 1 clinical trial for small cell lung cancer (SCLC) using a new T-cell engager drug. Diagnosed with aggressive Stage 4 SCLC after already undergoing treatment for a brain tumor, Patricia initially felt unheard about her declining health. After transferring to Roswell Park and meeting with medical oncologist Dr. Prantesh Jain, she learned about the clinical trial. T-cell engagers are a type of immunotherapy that works by directing a patient's own immune system T cells to target and destroy cancer cells. This specific study drug targets a protein called delta-like ligand 3 (DLL3), found on most SCLC cells. A year into the trial, Patricia's lung tumors are shrinking, with one 40% smaller, and there is currently no evidence of disease progression. She attributes her improved health and renewed hope to the trial and the supportive care received at Roswell Park.

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies Announces 95.5% Complete Response Rate for Non-Surgical Oral Cancer Therapy PRV111 in Phase 2 Trial

Privo Technologies has announced positive results from its CLN-004 Phase 2 trial for PRV111, a nanoengineered, cisplatin-releasing patch designed to treat non-invasive oral cancer and high-grade dysplasia. The study, conducted at four major U.S. hospitals, involved 22 patients with biopsy-confirmed conditions. Twenty-one of these patients (95.5%) achieved a centrally confirmed pathologic complete response, meaning no residual dysplastic cells were found after treatment. The remaining patient was downstaged to low-grade dysplasia. Crucially, all 22 patients avoided the need for standard-of-care surgery, with treated lesions resolving and mucosal surfaces regenerating without scarring or distortion. At a median follow-up of 14 months, no recurrences were observed, and some patients have maintained responses for over 21 months. The treatment was well-tolerated, with negligible systemic cisplatin exposure and primarily mild, transient oral symptoms reported as treatment-related adverse events.

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

A new research project, funded by IFAB and coordinated by Professor Giovanni Roti of the University of Parma, is developing a functional precision medicine platform to treat acute myeloid leukemia (AML). This initiative aims to move beyond conventional, often ineffective, treatments for AML, particularly in elderly patients. The project focuses on the individual variability of the disease, recognizing that cancer manifests differently in each patient. Researchers are utilizing advanced algorithms to test hundreds of non-commercialized pharmacological molecules on individual cancer cells. This approach significantly expands the scope of drug testing compared to the standard pool of about 15 drugs currently used for AML. The ultimate goal is to identify personalized therapeutic profiles that are more effective and can treat a larger percentage of patients who are currently considered untreatable. The project seeks to shift the paradigm from a one-size-fits-all treatment to therapies tailored to specific dise...